Recombinant il 33

Manufactured by BioLegend

Sourced in United States

Recombinant IL-33 is a cytokine that belongs to the IL-1 family. It is a key regulator of type 2 immune responses and plays a role in inflammatory processes.

Automatically generated - may contain errors

Lab products found in correlation

Facsaria, by BD (3 mentions) Il 12, by R&D Systems (2 mentions) Il 18, by R&D Systems (2 mentions) Recombinant chil3, by R&D Systems (2 mentions) Dnase 1, by Merck Group (2 mentions) Il 25, by R&D Systems (1 mentions) Il 33, by BioLegend (1 mentions) Anti dnp ige antibody, by Merck Group (1 mentions) Dnp hsa, by Merck Group (1 mentions) Ionomycin, by Merck Group (1 mentions) Phorbol myristate acetate (pma), by Merck Group (1 mentions) Alternaria alternata, by Stallergenes Greer (1 mentions) C57bl 6 mice, by Taconic Biosciences (1 mentions) Liberase tl, by Roche (1 mentions) Epcam microbeads, by Miltenyi Biotec (1 mentions) Cd4 cd62l t cell isolation kit, by Miltenyi Biotec (1 mentions) Cd45 microbeads, by Miltenyi Biotec (1 mentions) Anti cd3 clone ucht1, by BioLegend (1 mentions) Anti cd28 clone cd28, by BioLegend (1 mentions) Histopaque 1083, by Merck Group (1 mentions)

22 protocols using recombinant il 33

Probing ILC2 Activation by JWYPFS Serum

Check if the same lab product or an alternative is used in the 5 most similar protocols

The sorted ILC2s (80,000 cells/ml) were cultured in complete culture medium. ILC2s were treated with normal serum or different concentrations of JWYPFS-medicated serum for 12 h at 37°C with 5% CO₂. After 12 h of culture, recombinant IL-33 (20 ng/ml; BioLegend) was added for ILC2s stimulation for 4 h. Subsequently, the cells were harvested to measure levels of IRF4, GATA3, ST2 by Real-Time PCR. IL-5 and IL-13 in the cell supernatant was measured by ELISA.

Xue L., Li C., Ge G., Zhang S., Tian L., Wang Y., Zhang H., Ma Z, & Lu Z. (2021). Jia-Wei-Yu-Ping-Feng-San Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation in Allergic Asthma. Frontiers in Pharmacology, 12, 703724.

+ Open protocol

+ Expand

Helminth Infection Modulation by IL-33/IL-25

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were infected with 500 L3 N. brasiliensis larvae. On the day of infection and for an additional 3 days, mice were administered sterile PBS or 500ng recombinant IL-33 (Biolegend) or IL-25 (R&D Systems) i.p. Mice were euthanized 5 days post-infection and the small intestine was opened longitudinally, placed in HBSS at 37°C for 1 hour, and worms were manually enumerated.

Miller M.M., Patel P.S., Bao K., Danhorn T., O’Connor B, & Reinhardt R.L. (2020). BATF acts as an essential regulator of IL-25-responsive migratory ILC2 cell fate and function. Science immunology, 5(43), eaay3994.

+ Open protocol

+ Expand

Eosinophil Identification in UUO Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

To test whether the Siglec-F⁺ neutrophils could be eosinophils, the UUO mice were i.p. injected with 250 ng recombinant IL-33 (BioLegend) on postsurgical days 0, 1, 2, and 3.

Ryu S., Shin J.W., Kwon S., Lee J., Kim Y.C., Bae Y.S., Bae Y.S., Kim D.K., Kim Y.S., Yang S.H, & Kim H.Y. (2022). Siglec-F–expressing neutrophils are essential for creating a profibrotic microenvironment in renal fibrosis. The Journal of Clinical Investigation, 132(12), e156876.

+ Open protocol

+ Expand

Expanding ILC2 and Cytokine-Induced Plasticity

Check if the same lab product or an alternative is used in the 5 most similar protocols

To expand ILC2, C57BL/6 or Rag2^−/− mice were treated intranasally (i.n.) with 100 ng of recombinant IL-33 (Biolegend) each day for 5 consecutive days. For the cytokine-based plasticity model, C57BL/6 or Rag2^−/− mice were treated i.n. with different combinations of cytokines specified in figures legends at day 1, 3, 5, 8 and sacrificed at day 9: 100 ng of IL-12 (R&D), IL-18 (R&D), IL-33 (Biolegend) or 20 μg of NMU (US Biological) per mouse and per instillation.

Corral D., Charton A., Krauss M.Z., Blanquart E., Levillain F., Lefrançais E., Sneperger T., Vahlas Z., Girard J.P., Eberl G., Poquet Y., Guéry J.C., Argüello R.J., Belkaid Y., Mayer-Barber K.D., Hepworth M.R., Neyrolles O, & Hudrisier D. (2022). ILC precursors differentiate into metabolically distinct ILC1-like cells during Mycobacterium tuberculosis infection. Cell Reports, 39(3), 110715.

+ Open protocol

+ Expand

Mast Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

BMMCs and PMCs were stimulated for 4 h with the following: 1 µg/ml IgE-anti DNP antibody (Sigma) and 0.2 µg/ml HSA-DNP (Sigma) or 20 nM PMA (Sigma) and 2 µM ionomycin (Sigma), and/or 0.1 ng/ml recombinant IL-33 (Biolegend). When used in combination, IL-33 and HSA-DNP were added simultaneously. HMC-1.1 and 1.2 cells were stimulated for 4 h with 20 nM PMA and 2 µM ionomycin.

Leoni C., Bataclan M., Ito-Kureha T., Heissmeyer V, & Monticelli S. (2023). The mRNA methyltransferase Mettl3 modulates cytokine mRNA stability and limits functional responses in mast cells. Nature Communications, 14, 3862.

+ Open protocol

+ Expand

Adoptive Transfer of M2 Macrophages or IL-33 Treatment

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thirty days post-infection, mice received 2 × 10⁶ bone marrow-derived M2 macrophages by the intra-tracheal route or were treated with recombinant IL-33 (BioLegend, San Diego, CA) (1 μg/mouse) by the intranasal route (five doses total at 2-day intervals) as previously reported51 (link)62 (link). A CFU assay was performed at 8 days post-adoptive cell transfer or 24 hours after the last treatment with IL-33.

Piñeros A.R., Campos L.W., Fonseca D.M., Bertolini T.B., Gembre A.F., Prado R.Q., Alves-Filho J.C., Ramos S.G., Russo M, & Bonato V.L. (2017). M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection. Scientific Reports, 7, 41240.

+ Open protocol

+ Expand

Allergic Airway Inflammation in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Eight-week-old wild type C57BL/6 mice were purchased from Taconic (Hudson, NY). RAGE KO mice congenic with the C57BL/6 strain were provided by Dr. A. Bierhaus (University of Heidelberg), and a breeding colony was established (25 (link), 26 (link)). Animal studies were carried out under the National Research Council’s guidelines in the Guide for the Care and Use of Laboratory Animals, with oversight by the University of Pittsburgh Institutional Animal Care and Use Committee. HDM and Alternaria alternata extracts were purchased from Greer Laboratories. Recombinant IL-33 was purchased from BioLegend.

Oczypok E.A., Milutinovic P.S., Alcorn J.F., Khare A., Crum L.T., Manni M.L., Epperly M.W., Pawluk A.M., Ray A, & Oury T.D. (2015). Pulmonary receptor for advanced glycation endproducts promotes asthma pathogenesis via IL-33 and accumulation of group 2 innate lymphoid cells. The Journal of allergy and clinical immunology, 136(3), 747-756.e4.

+ Open protocol

+ Expand

Chronic Aspergillus fumigatus Sensitization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were sedated with isoflurane and sensitized intranasally (i.n.) to A. fumigatus protein extract (Greer) in PBS (25μg/25μl PBS) 3 times per week for 6-weeks to develop a chronic response. Control mice were sensitized i.n. with PBS at these time points. To generate a memory response, mice were rested after a 6-week chronic sensitization for either 6 or 12-weeks without additional manipulation. Recall responses were induced with 2 doses of A. fumigatus protein (25μg/25μl PBS) or PBS as control separated by 24 hours with analysis 24 hours after the last challenge. An additional recall time course was completed where mice received no challenge or 1 recall challenge (8 hours), 2 recall challenges (8 and 24 hours), or 3 recall challenges (8, 24, and 48 hours) before analysis. In some experiments mice received two doses of recombinant IL-33 (50μg/25μl PBS, BioLegend) as a recall challenge where indicated. In some experiments, mice were treated daily with FTY720 (1mg/kg) diluted in ddH2O delivered via intraperitoneal injection. For chronic blockade of memory T cell migration, mice were treated with FTY720 daily or vehicle control for 21 days prior to analysis.

Ulrich B.J., Kharwadkar R., Chu M., Pajulas A., Muralidharan C., Koh B., Fu Y., Gao H., Hayes T.A., Zhou H.M., Goplen N.P., Nelson A.S., Liu Y., Linnemann A.K., Turner M.J., Licona-Limón P., Flavell R.A., Sun J, & Kaplan M.H. (2022). Allergic airway recall responses require IL-9 from resident memory CD4+ T cells. Science immunology, 7(69), eabg9296.

+ Open protocol

+ Expand

Modulating Amebic Infection Using IL-33, sST2, and Chil3

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were administered 0.75 μg of recombinant IL-33 (BioLegend, San Diego, CA) or PBS via intraperitoneal injection daily beginning at 3 days before amebic challenge up until 1 day before harvest. For sST2 experiments, mice were treated with 5ug/mouse of ST2-Fc fusion (R&D Systems, Catalog # 1004-MR-050) or Fc control for four days (day −1, day 0, day+1, and day+2 of amebic challenge) intraperitoneally. For the Chil3 treatment, mice were administered 6 doses (on day −2, −1, 0, +1, +2 +3) of recombinant Chil3 (5ug/dose) (R&D Systems) via intraperitoneal injection.

Uddin M.J., Leslie J.L., Burgess S.L., Oakland N., Thompson B., Abhyankar M., Revilla J., Frisbee A., Donlan A.N., Kumar P, & Petri Jr W.A. (2021). The IL-33-ILC2 pathway protects from amebic colitis. Mucosal Immunology, 15(1), 165-175.

+ Open protocol

+ Expand

Induction and Adoptive Transfer of Lung ILC2

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

To induce ILC2 in vivo, naive C57BL/6 mice were inoculated intranasally with 1 μg recombinant IL-33 (BioLegend) on five consecutive days. Lung tissue was digested with Liberase TL (Roche, 0.2 mg/ml) and DNAse I (Sigma, 0.5 mg/ml) for 45 min at 37°C under rotation. Total lung cells were stained with lineage cocktail Abs (anti-CD3ε, anti-CD11b, anti-CD11c, anti-NK1.1, anti-siglec F, anti-FcεRI, anti-B220), anti-CD45, anti-ST2 and anti-ICOS Abs for 30 min at 4°C. ILC2 were sorted by FACSAria (BD Biosciences) (purity >98%). ILC2 were defined as CD45⁺ICOS⁺ST2⁺ lymphoid cells negative for lineage markers as described previously [18 (link)]. For adoptive transfer, 2×10⁶ freshly purified ILC2 were injected i.v. to naive C57BL/6 mice, which were infected i.v. with 10⁴ pRBC 24 h later. Mice were then treated with IL-33 (0.2 μg, i.p.) 30 min and 24 h after cell transfer.

Besnard A.G., Guabiraba R., Niedbala W., Palomo J., Reverchon F., Shaw T.N., Couper K.N., Ryffel B, & Liew F.Y. (2015). IL-33-Mediated Protection against Experimental Cerebral Malaria Is Linked to Induction of Type 2 Innate Lymphoid Cells, M2 Macrophages and Regulatory T Cells. PLoS Pathogens, 11(2), e1004607.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!